| Related LncRNAs | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| ID | lncRNA Name | Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source |
| EL0289 | CDKN2B-AS1 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs (rs2891168, A>G) in the ANRIL locus on chromosome 9p. | 18048406 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | Recent studies showed that single nucleotide polymorphisms (rs3217992, A>G;rs1063192, C>T) mapping in the vicinity of ANRIL are linked to a wide spectrum of conditions, including cardiovascular disease, ischemic stroke, type 2 diabetes, frailty and Alzheimer's disease. | 17463248 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | Association identified by GWAS. | 17463249 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of ANRIL. | 20386740 | LncRNADisease Lnc2Cancer |
| EL0289 | CDKN2B-AS1 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | Common disease genomewide association studies (GWAS) have surprisingly identified the ANRIL gene as a genetic susceptibility locus (rs3217992, A>G;rs1063192, C>T) shared associated by coronary disease, intracranial aneurysm and also type 2 diabetes. | 20956613 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | type 2 diabetes mellitus | N/A | N/A | N/A | locus | A genetic susceptibility locus. | 20956613 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | Interestingly, genome wide association studies (GWAS) identified several variants in the intergenic region encompassing ANRIL to be associated with several diseases such as coronary heart disease, intracranial aneurysm, many type of cancers and T5D | 22928560 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | type 2 diabetes mellitus | N/A | N/A | N/A | locus | Furthermore, genome wide association studies have identified the ANRIL gene as a risk locus for coronary disease, intracranial aneurism, type 2 diabetes and several cancers including glioma. | 24624135 | LncRNADisease |
| EL0526 | GAS5 | type 2 diabetes mellitus | lncRNA arrays, quantitative PCR | Serum samples obtained from 96 participating veterans at JAH VA | N/A | expression | Decreased GAS5 levels in serum were associated with diabetes in a cohort of US military veterans. | 26674525 | |
| EL0556 | H19 | type 2 diabetes mellitus | N/A | muscle of human subjects with type-2 diabetes and insulin resistant rodents. | down-regulated | expression | H19 is significantly decreased in muscle of human subjects with type-2 diabetes and insulin resistant rodents. This decrease leads to increased bioavailability of let-7, causing diminished expression of let-7 targets, which is recapitulated in vitro where H19 depletion results in impaired insulin signaling and decreased glucose uptake. | 25399420 | |
| EL0652 | LINC00271 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | Association identified by GWAS. | 17668382 | LncRNADisease |
| EL0693 | LINC01370 | type 2 diabetes mellitus | N/A | N/A | N/A | regulation | Depletion of HI-LNC25, a 尾 cell-specific lncRNA, downregulated GLIS3 mRNA, thus exemplifying a gene regulatory function of islet lncRNAs. Finally, selected islet lncRNAs were dysregulated in type 2 diabetes or mapped to genetic loci underlying diabetes susceptibility. | 23040067 | LncRNADisease |
| EL0861 | MEG3 | type 2 diabetes mellitus | real-time PCR, western blotting | High-fat diet mice, ob/ob mice and mice primary hepatocytes | up-regulated | interaction | MEG3 interference could reverse the up-regulation of triglyceride as well as impaired glucose tolerance and down-regulation of glucogen content in high-fat diet mice or ob/ob mice. Upregulation of lncRNA MEG3 enhances hepatic insulin resistance via increasing foxO1 expression, suggesting that MEG3 may be a potential target and therapeutic strategy for diabetes. | 26603935 | |
| EL0984 | NONRATT021972 | type 2 diabetes mellitus | N/A | Type 2 diabetes mellitus (T2DM) rat model, T2DM patient serum | up-regulated | interaction | MWT and TWL in T2DM rats treated with NONRATT021972 siRNA were higher compared with those in T2DM rats. NONRATT021972 siRNA treatment may suppress the upregulated expression and activation of the P2X3 receptor and reduce the hyperalgesia potentiated by the pro-inflammatory cytokine TNF-α in T2DM rats. | 26742527 | |
| EL1034 | P2rx3 | type 2 diabetes mellitus | rat lncRNA array profiling | type 2 diabetic rats | up-regulated | N/A | lncRNA uc.48+ siRNA regulating the expression of P2X7 and ERK signaling in SCG. | 27118262 | |
| EL1062 | PDZRN3-AS1 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | SNP rs11128347 (C>G) in PDZRN3 is associated with African-Americans with type 2 diabetes. | 21546767 | LncRNADisease |
| EL1102 | PVT1 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | Identification of PVT1 (rs2720709, A>G) as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study. | 17395743 | LncRNADisease |
| EL1102 | PVT1 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | There is association between variants (rs2720709, A>G) in the plasmacytoma variant translocation 1 gene (PVT1) and end-stage renal disease (ESRD) attributed to both type 1 and type 2 diabetes. | 21526116 | LncRNADisease |